PMA device
Obalon Balloon System
Medtimo, Inc. · Implant, Intragastric For Morbid Obesity (LTI, Class III) · First FDA decision Sep 8, 2016, newest Jul 18, 2022Obesity
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
11
PMA pathway
Device trials
9
Naming "Obalon"
MAUDE reports
64
Brand "Obalon", since 2015
PubMed studies
23
Mentioning "Obalon"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Obalon Balloon System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 11 decisions filed under this name.
- Obalon Balloon SystemPMA supplement
P160001-S047 · Decided Jul 18, 2022 · 180 days after receipt · Normal 180 Day Track No User Fee
Device type: IMPLANT, INTRAGASTRIC FOR MORBID OBESITY (LTI) · GI, Urology & Nephrology
- Obalon Balloon SystemPMA supplement
P160001-S042 · Decided Aug 8, 2019 · 55 days after receipt · Normal 180 Day Track No User Fee
Device type: IMPLANT, INTRAGASTRIC FOR MORBID OBESITY (LTI) · GI, Urology & Nephrology
- OBALON BALLOON SYSTEMPMA supplement
P160001-S038 · Decided May 29, 2019 · 40 days after receipt · Normal 180 Day Track No User Fee
Device type: IMPLANT, INTRAGASTRIC FOR MORBID OBESITY (LTI) · GI, Urology & Nephrology
3 more FDA decisions with a free account
Older decisions: P160001-S020, P160001-S018, P160001-S003, P160001-S001, P160001
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Bariatric Surgery for the Treatment of Morbid Obesity - Facility Certification RequirementNational analysisReview closedCAG-00250R3Updated Sep 16, 2026
- Bariatric Surgery for the Treatment of Morbid ObesityNational analysisReview closedCAG-00250R2Updated Sep 16, 2026
- Bariatric Surgery for the Treatment of Morbid ObesityNational analysisReview closedCAG-00250RUpdated Sep 16, 2026
- Bariatric Surgery for Treatment of Co-Morbid Conditions Related to Morbid ObesityNational determinationOn the books100.1Updated Apr 9, 2025
- Bariatric Surgical Management of Morbid ObesityLocal determinationIn effectL35022Novitas Solutions, Inc.Updated May 7, 2021
- Surgical Management of Morbid ObesityLocal determinationIn effectL33411First Coast Service Options, Inc.Updated Oct 2, 2019
Clinical trials
Device studies on ClinicalTrials.gov that name "Obalon", any status and sponsor, newest update first.
University of Colorado, DenverAcademic, hospital or other
NCT04306445 · 3 participants · Start Mar 2, 2020 · Primary completion Feb 22, 2024
Device: GF-IGB: Obalon Balloon · For: Obesity
Sites: Aurora, Colorado
Cleveland Clinic LondonAcademic, hospital or other
NCT06305208 · 300 participants (planned) · Start Feb 1, 2024 · Primary completion Feb 1, 2034
Device: Endoscopic gastric suturing; Endoscopic gastric plication and 4 more · For: Obesity; Diabetes Mellitus, Type 2
Sites: London, United Kingdom
- Obalon Balloon System Post-Approval StudyStatus unknown
Obalon Therapeutics, Inc.Not on our public-company list
NCT03570034 · 201 participants · Start Jun 15, 2018 · Primary completion Sep 13, 2020
Device: Obalon Balloon System · For: Obesity
Sites: Fountain Valley, California; Glendale, California; Los Gatos, California · 15 sites in all
6 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Obalon", and for the whole product code for context.
This brand
64 reports: 41 malfunction, 23 injury, 0 death
Whole product code LTI
5,233 reports: 2,779 malfunction, 2,372 injury, 70 death
Newest reports for this brand
- OBALON GASTRIC BALLOONMalfunction
MW5095931 · Received Aug 6, 2020 · Event dated Jul 23, 2020
Device type: Implant, Intragastric For Morbid Obesity (LTI)
Device problem as coded: Deflation Problem; Migration or Expulsion of Device
Patient problem as coded: No Known Impact Or Consequence To Patient
- OBALON BALLOON SYSTEMMalfunction
3009256831-2020-00010 · Received Apr 9, 2020 · Event dated Mar 6, 2020
Device type: Implant, Intragastric For Morbid Obesity (LTI)
Device problem as coded: Use of Device Problem
Patient problem as coded: Hiccups
- OBALON BALLOON SYSTEMMalfunction
3009256831-2020-00007 · Received Apr 1, 2020 · Event dated Mar 6, 2020
Device type: Implant, Intragastric For Morbid Obesity (LTI)
Device problem as coded: Leak/Splash; Migration
Patient problem as coded: No Consequences Or Impact To Patient
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Obalon"[tiab]. The summary above synthesizes these.
- Advances in endoscopic balloon therapy for weight loss and its limitations.
Vyas D, Deshpande K, Pandya Y · World J Gastroenterol · 2017Editorial
- Six intragastric balloons: Which to choose?
Stavrou G, Shrewsbury A, Kotzampassi K · World J Gastrointest Endosc · 2021Review
- Drugs and devices for weight management.
Med Lett Drugs Ther · 2022
- Drugs and devices for weight management.
Med Lett Drugs Ther · 2025
- Obalon intragastric balloon in the treatment of paediatric obesity: a pilot study.
Nobili V, Della Corte C, Liccardo D, et al. · Pediatr Obes · 2015Evaluation Study
- Obalon Balloon Removal: A Novel Operative Technique.
Reddy V, Nguyen A, Ibikunle C · Surg Innov · 2021Letter
- Progress in the study of intragastric occupancy device for weight reduction.
Yu Q, Cao Y, Wang Z, et al. · Zhong Nan Da Xue Xue Bao Yi Xue Ban · 2023
- Fluid-Filled Versus Gas-Filled Intragastric Balloons as Obesity Interventions: a Network Meta-analysis of Randomized Trials.
Bazerbachi F, Haffar S, Sawas T, et al. · Obes Surg · 2018Systematic Review, Network Meta-Analysis
- Obalon intragastric balloon in the treatment of paediatric obesity: a pilot study.
Nobili V, Della Corte C, Liccardo D, et al. · Pediatr Obes · 2018Published Erratum
- Obalon Balloon System--another gastric balloon for weight loss.
Med Lett Drugs Ther · 2017
- Filling the Void: A Review of Intragastric Balloons for Obesity.
Laing P, Pham T, Taylor LJ, et al. · Dig Dis Sci · 2017Review
- Endoscopic Bariatric Therapies: Intragastric Balloons, Tissue Apposition, and Aspiration Therapy.
Turkeltaub JA, Edmundowicz SA · Curr Treat Options Gastroenterol · 2019Review
Other devices of this type
Also filed under product code LTI.
- Lap-Band Adjustable Gastric Banding SystemMedtimo, Inc. · PMA 2023
- Orbera Intragastric BalloonBoston Scientific Corporation · PMA 2026
- Bioenterics Lap-Band Adjustable Gastric Banding SystemMedtimo, Inc. · PMA 2003
- ReShape Integrated Dual Balloon SystemBoston Scientific Corporation · PMA 2018
- Allurion Gastric Balloon SystemAllurion Technologies, Inc. · PMA 2026
- Spatz3 Adjustable Balloon SystemSpatz Fgia, Inc. · PMA 2023
- Ethicon Endo-Surgery Curved Adjustable Gastric with Sutureless Port and ApplierObtech Medical GmbH · PMA 2016
- Realize Adjustable Gastric BandObtech Medical GmbH · PMA 2011
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.